{"id":"NCT04574362","sponsor":"Pfizer","briefTitle":"Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine","officialTitle":"BHV3000-310: Phase 3: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-10-22","primaryCompletion":"2021-11-24","completion":"2021-12-16","firstPosted":"2020-10-05","resultsPosted":"2023-12-14","lastUpdate":"2023-12-14"},"enrollment":1648,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Migraine"],"interventions":[{"type":"DRUG","name":"Rimegepant","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rimegepant 75mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This trial is to determine whether BHV3000 (rimegepant) 75mg is safe and effictive as a treatment for acute migraine in Chinese and Korean patients","primaryOutcome":{"measure":"Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-dose","timeFrame":"2 hours post-dose","effectByArm":[{"arm":"Rimegepant 75 mg","deltaMin":19.8,"sd":null},{"arm":"Placebo","deltaMin":10.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":90,"countries":["China","South Korea"]},"refs":{"pmids":["38627638","37210098"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=BHV3000-310"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":668},"commonTop":["Nausea","Protein urine present","Urinary tract infection","Blood creatine phosphokinase increased","Upper respiratory tract infection"]}}